Market Closed -
Nasdaq
21:30:00 30/05/2024 BST
|
5-day change
|
1st Jan Change
|
7.15
USD
|
-5.30%
|
|
-5.30%
|
-23.12%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
15,646
|
6,329
|
1,632
|
696
|
Enterprise Value (EV)
1 |
13,430
|
4,919
|
775.6
|
79.79
|
P/E ratio
|
-21.9
x
|
-7.92
x
|
-1.66
x
|
-1.03
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.4
x
|
12.5
x
|
2.9
x
|
1.29
x
|
EV / Revenue
|
31.2
x
|
9.68
x
|
1.38
x
|
0.15
x
|
EV / EBITDA
|
-35.3
x
|
-6.54
x
|
-0.9
x
|
-0.15
x
|
EV / FCF
|
-621
x
|
-16.1
x
|
-3.52
x
|
-1.39
x
|
FCF Yield
|
-0.16%
|
-6.21%
|
-28.4%
|
-72%
|
Price to Book
|
6.52
x
|
3.45
x
|
1.38
x
|
0.88
x
|
Nbr of stocks (in thousands)
|
10,380
|
10,455
|
10,519
|
10,544
|
Reference price
2 |
1,507
|
605.4
|
155.2
|
66.00
|
Announcement Date
|
23/03/21
|
29/04/22
|
20/04/23
|
29/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
208.9
|
381.7
|
429.9
|
507.9
|
563.2
|
537.4
|
EBITDA
1 |
-136.9
|
-138.3
|
-379.9
|
-752.5
|
-859.7
|
-537.9
|
EBIT
1 |
-161.4
|
-169.1
|
-412.4
|
-797.1
|
-980.4
|
-669.3
|
Operating Margin
|
-77.27%
|
-44.3%
|
-95.93%
|
-156.94%
|
-174.07%
|
-124.54%
|
Earnings before Tax (EBT)
1 |
-177.5
|
-169.2
|
-407.2
|
-795.8
|
-969.2
|
-651.3
|
Net income
1 |
-177.5
|
-169.2
|
-407.2
|
-796.7
|
-971.2
|
-653.7
|
Net margin
|
-84.98%
|
-44.32%
|
-94.73%
|
-156.87%
|
-172.44%
|
-121.63%
|
EPS
2 |
-103.8
|
-142.3
|
-68.76
|
-76.45
|
-93.47
|
-63.84
|
Free Cash Flow
1 |
-111.4
|
-222.1
|
-21.63
|
-305.3
|
-220.2
|
-57.45
|
FCF margin
|
-53.34%
|
-58.2%
|
-5.03%
|
-60.11%
|
-39.09%
|
-10.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/12/19
|
22/05/20
|
23/03/21
|
29/04/22
|
20/04/23
|
29/04/24
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
126.6
|
147.3
|
135.5
|
130.8
|
154.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-171
|
-
|
-262.9
|
-
|
-234.6
|
Operating Margin
|
-135.09%
|
-
|
-193.96%
|
-
|
-151.74%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-261.4
|
-
|
-231.5
|
Net income
1 |
-
|
-
|
-261.4
|
-
|
-231.5
|
Net margin
|
-
|
-
|
-192.87%
|
-
|
-149.7%
|
EPS
2 |
-
|
-
|
-25.00
|
-25.00
|
-23.30
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/11/21
|
22/03/22
|
31/05/22
|
31/08/22
|
16/11/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
136
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
343
|
2,216
|
1,410
|
857
|
616
|
Leverage (Debt/EBITDA)
|
-0.9936
x
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-111
|
-222
|
-21.6
|
-305
|
-220
|
-57.5
|
ROE (net income / shareholders' equity)
|
-220%
|
-51.9%
|
-26.4%
|
-37.3%
|
-64.7%
|
-67.9%
|
ROA (Net income/ Total Assets)
|
-26.1%
|
-17.3%
|
-14.7%
|
-20.2%
|
-31.7%
|
-31.8%
|
Assets
1 |
680.1
|
976.6
|
2,773
|
3,951
|
3,064
|
2,053
|
Book Value Per Share
2 |
-260.0
|
-356.0
|
231.0
|
176.0
|
113.0
|
75.00
|
Cash Flow per Share
2 |
40.30
|
37.60
|
181.0
|
136.0
|
88.20
|
60.00
|
Capex
1 |
24.6
|
45.3
|
75.6
|
211
|
70.3
|
8.1
|
Capex / Sales
|
11.76%
|
11.88%
|
17.58%
|
41.53%
|
12.48%
|
1.51%
|
Announcement Date
|
09/12/19
|
22/05/20
|
23/03/21
|
29/04/22
|
20/04/23
|
29/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -23.12% | 73.35M | | -24.16% | 7.76B | | +68.65% | 4.33B | | -2.98% | 2.64B | | +2.72% | 2.63B | | -46.17% | 2.16B | | -22.12% | 1.46B | | +13.62% | 1.17B | | -43.81% | 1.14B | | +20.41% | 999M |
Medical & Diagnostic Laboratories
|